Cell wall inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Cell wall inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Cell wall inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cell wall inhibitors: Overview
Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the ?-lactams and glycopeptide antibiotics. They control Gram-negative and Gram-positive bacterial infection by inhibition of cell wall synthesis and have been used for many decades.
Report Highlights
This segment of the Cell wall inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cell wall inhibitors Emerging Drugs
The FDA has granted CONTEPO Qualified Infectious Disease Product (QIDP) and Fast Track designations for: Complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP), acute bacterial skin and skin structure infections (ABSSSI). It is currently in preregistration phase of development and is being developed by Nabriva Therapeutics.
It is currently in phase III stage of development is being developed by Spero Therapeutics.
Further product details are provided in the report……..
Cell wall inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cell wall inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Cell wall inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cell wall inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell wall inhibitors drugs.
Cell wall inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Cell wall inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Cell wall inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cell wall inhibitors: Overview
Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the ?-lactams and glycopeptide antibiotics. They control Gram-negative and Gram-positive bacterial infection by inhibition of cell wall synthesis and have been used for many decades.
- ?-Lactam antibiotics: They are a broad class of antibiotics that inhibit cell wall synthesis, consisting of all antibiotic agents that contain a ?-lactam nucleus in their molecular structures. Some commonly used ?-Lactam antibiotics include penicillins, ciclosporins, monobactams, and carbapenems. They are bactericidal and act by inhibiting the synthesis of peptidoglycan layers in the bacterial cell wall.
- Glycopeptide antibiotics: They are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Some important glycopeptide antibiotics include vancomycin, teicoplanin, telavancin, bleomycin, and ramoplanin. They inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cell wall inhibitors R&D. The therapies under development are focused on novel approaches for Cell wall inhibitors.
This segment of the Cell wall inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cell wall inhibitors Emerging Drugs
- CONTEPO: Nabriva Therapeutics
The FDA has granted CONTEPO Qualified Infectious Disease Product (QIDP) and Fast Track designations for: Complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP), acute bacterial skin and skin structure infections (ABSSSI). It is currently in preregistration phase of development and is being developed by Nabriva Therapeutics.
- Tebipenem pivoxil: Spero Therapeutics
It is currently in phase III stage of development is being developed by Spero Therapeutics.
Further product details are provided in the report……..
Cell wall inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cell wall inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Cell wall inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Cell wall inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cell wall inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell wall inhibitors drugs.
Cell wall inhibitors Report Insights
- Cell wall inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Cell wall inhibitors drugs?
- How many Cell wall inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Cell wall inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cell wall inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cell wall inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Recce Pharmaceuticals
- Spero Therapeutics
- Nabriva Therapeutics
- Karveel Pharmaceuticals
- Seachaid Pharmaceuticals
- RECCE-327
- RECCE-111
- Tebipenem pivoxil
- CONTEPO
- SNP021062
- SP1001
- SP-2078
Introduction
Executive Summary
Cell wall inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cell wall inhibitors– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cell wall inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cell wall inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tebipenem pivoxil: Spero Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
RECCE-111: Recce Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cell wall inhibitors Key Companies
Cell wall inhibitors Key Products
Cell wall inhibitors- Unmet Needs
Cell wall inhibitors- Market Drivers and Barriers
Cell wall inhibitors- Future Perspectives and Conclusion
Cell wall inhibitors Analyst Views
Cell wall inhibitors Key Companies
Appendix
Executive Summary
Cell wall inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cell wall inhibitors– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cell wall inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cell wall inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tebipenem pivoxil: Spero Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
RECCE-111: Recce Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cell wall inhibitors Key Companies
Cell wall inhibitors Key Products
Cell wall inhibitors- Unmet Needs
Cell wall inhibitors- Market Drivers and Barriers
Cell wall inhibitors- Future Perspectives and Conclusion
Cell wall inhibitors Analyst Views
Cell wall inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cell wall inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cell wall inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cell wall inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cell wall inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
